New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Lymphoma

Lymphoma Regimens


Haematology regimens within the SACT Regimen Library currently only specify mandatory supportive care medicines to be used for all patients, unless contraindicated. A clinically equivalent mandatory medicine may be substituted as per institutional practice.

Supportive care factors are included in all regimens, with the appropriate dimensions (value) as Recommended (for most patients), Consider (for some patients after clinical risk assessment), or with guidance (e.g. emetogenicity classification or if variable). Centres are expected to include antiemetics and other supportive care medicines within their own prescribing systems.

Published

Name Version Date
LYM - GCD [gemcitabine, cARBOplatin and dexamethasone]1.0.021/06/2023
LYM - GDP [gemcitabine, dexamethasone and cISplatin]1.0.021/06/2023
LYM - GemOx [gemcitabine and oxaliplatin]1.0.002/08/2023
LYM - PEP-C [prEDNISone, CYCLOPHOSPHamide, etoposide and procarbazine]1.0.019/06/2023
LYM - vinORELBine and gemcitabine2.0.023/10/2023
LYM Relapsed - DHAC [dexamethasone, high dose cytarabine and cARBOplatin]1.0.028/07/2023
LYM Relapsed - DHAP [dexamethasone, high dose cytarabine and cISplatin]1.0.003/10/2023
LYM Relapsed - GIVE [filgrastim, IFOSFamide, etoposide and epirubicin]1.0.003/10/2023
LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide]2.0.028/07/2023
LYM Relapsed/Refractory - pembrolizumab Q3W [flat dosing]1.0.012/08/2023

Hodgkin lymphoma Regimens


Published

Name Version Date
LYM HL Advanced - ChIVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone]1.0.019/09/2023

Non-Hodgkin lymphoma Regimens


Published

Name Version Date
LYM NHL - CHOP21 [CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]1.0.026/06/2023
LYM NHL - vinCRISTine and prEDNISone [pre-phase]1.0.009/10/2023
LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]1.0.022/04/2024
LYM NHL B-cell - bendamustine and oBINUTUZumab1.0.004/12/2023
LYM NHL B-cell - CYCLOPHOSPHamide and prEDNIsone [pre-phase]1.0.008/10/2023
LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels]1.0.022/04/2024
LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab1.0.015/11/2023
LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV etoposide]1.0.022/06/2023
LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV/oral etoposide]1.0.022/06/2023
LYM NHL B-cell - R-CHOP14 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]1.0.022/06/2023
LYM NHL B-cell - R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]1.0.026/06/2023
LYM NHL B-cell - R-CVP [RITUximab, CYCLOPHOSPHamide, vinCRISTine and prEDNISone]1.0.026/06/2023
LYM NHL B-cell - R-GCVP [RITUximab, gemcitabine, CYCLOPHOSPHamide, vinCRISTine and prEDNISone]1.0.021/06/2023
LYM NHL B-cell - R-GDP [RITUximab, gemcitabine, dexamethasone and cISplatin]1.0.022/06/2023
LYM NHL B-cell - R-GemOX [RITUximab, gemcitabine and oxaliplatin]1.0.021/06/2023
LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]1.0.017/09/2023
LYM NHL B-cell - RITUximab and bendamustine1.0.023/10/2023
LYM NHL B-cell - RITUximab Maintenance Q8W1.0.023/10/2023
LYM NHL B-cell - RITUximab Q1W1.0.023/10/2023
LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNISone] [IV etoposide]1.0.026/06/2023
LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNIsone] [IV/oral etoposide]1.0.026/06/2023
LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenström macroglobulinema]1.0.007/05/2023
LYM NHL B-cell MCL - ibrutinib1.0.007/05/2023
LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine]1.0.008/05/2023
LYM NHL B-cell PCNSL - high dose metHOTREXATe 8 g/m22.0.007/01/2024
LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction1.0.007/01/2024
LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine]1.0.007/01/2024
LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over]2.0.007/01/2024
LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine1.0.007/01/2024
LYM NHL B-cell PCNSL Relapsed - modified CYVE [cytarabine and etoposide]1.0.024/07/2023
LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide]1.0.023/10/2023
LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis]1.0.007/01/2024
LYM NHL B-cell Relapsed - R-DHAC [RITUximab, dexamethasone, high dose cytarabine and cARBOplatin]1.0.028/07/2023
LYM NHL B-cell Relapsed - R-DHAP [RITUximab, dexamethasone, high dose cytarabine and cISplatin]1.0.003/10/2023
LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide]2.0.028/07/2023
LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase]1.0.003/12/2023
LYM NHL NK/T-cell Extra Nodal - Level 1 [67%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type]1.0.003/10/2023
LYM NHL NK/T-cell Extra Nodal - Level 2 [100%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type]1.0.003/10/2023
LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide]2.0.022/06/2023
LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide]2.0.022/06/2023
LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide]1.0.026/06/2023
LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide]1.0.026/06/2023